Antares Pharma to Present at the Cowen and Company 37th Annual Healthcare Conference
February 28 2017 - 7:00AM
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Robert F.
Apple, President and Chief Executive Officer, will present at the
Cowen and Company 37th Annual Healthcare Conference on Monday March
6, 2017 at 2:40 pm Eastern Time.
A live webcast of the presentation will be
available via the “Investor Information/Webcasts” page of the
Antares website, www.antarespharma.com. A replay of the webcast
will also be archived on Antares’ website for 90 days following the
presentation.
About Antares Pharma
Antares Pharma focuses on self-administered
parenteral pharmaceutical products. The Company’s product, OTREXUP®
(methotrexate) injection for subcutaneous use, is approved in the
U.S. for the treatment of adults with severe active rheumatoid
arthritis, children with active polyarticular juvenile idiopathic
arthritis and adults with severe recalcitrant psoriasis. The
Company’s product Sumatriptan Injection USP, is approved in the
U.S. for the acute treatment of migraine and cluster headache and
is distributed by Teva Pharmaceutical Industries, Ltd. (Teva).
Antares Pharma is also developing QuickShot® Testosterone for
testosterone replacement therapy and has filed a New Drug
Application to the Food and Drug Administration. The Company's
technology platforms include VIBEX® disposable auto injectors,
disposable multi-use pen injectors and reusable needle-free
injectors. Antares Pharma has a multi-product deal with Teva that
includes VIBEX® epinephrine, exenatide multi-dose pen, and
teriparatide multi-dose pen. Our reusable needle-free injector for
use with human growth hormone (hGH) is sold worldwide by Ferring
B.V. The Company is also working with AMAG Pharmaceuticals on a
subcutaneous method for administering Makena, a progesterone
product indicated for use in lowering the risk of pre-term
birth. For more information, visit www.antarespharma.com.
SAFE HARBOR STATEMENT UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are subject to certain risks
and uncertainties that can cause actual results to differ
materially from those described. Factors that may cause such
differences include, but are not limited to: the timing and outcome
of the U.S. Food and Drug Administration (“FDA”) review of the QST
NDA, FDA approval of the QST NDA and future market acceptance and
revenue for QST; the outcome of the pending patent litigation
between Teva Pharmaceutical Industries, Ltd. (Teva) and Eli Lilly
and Company regarding the Teriparatide multi-dose pen; FDA action
with respect to Teva’s Abbreviated New Drug Application (“ANDA”)
for the Teriparatide multi-dose pen and the timing and approval, if
any, by the FDA of the same; Teva’s ability to adequately and
timely respond to the Complete Response Letter received from the
FDA for the VIBEX® epinephrine pen ANDA and approval by the FDA of
the same, the timing and therapeutic equivalence rating thereof,
and any future purchase orders and revenue pre or post FDA
approval; Teva’s ability to successfully commercialize VIBEX®
Sumatriptan Injection USP and the amount of revenue from the same;
FDA action with respect to Teva’s ANDA filed for the Exenatide pen
and future revenue from the same; continued growth of prescriptions
and sales of OTREXUP®; the timing and results of the
development project with AMAG Pharmaceuticals for an auto injector
for Makena; the timing and results of research projects, clinical
trials, and product candidates in development; actions by the FDA
or other regulatory agencies with the respect to the Company’s
products or product candidates of its partners; continued growth in
product, development, licensing and royalty revenue; the Company’s
ability to obtain financial and other resources for its research,
development, clinical, and commercial activities and other
statements regarding matters that are not historical facts, and
involve predictions. These statements involve known and unknown
risks, uncertainties and other factors that may cause actual
results, performance, achievements or prospects to be materially
different from any future results, performance, achievements or
prospects expressed in or implied by such forward-looking
statements. In some cases you can identify forward-looking
statements by terminology such as "may", "will", "should", "would",
"expect", "intend", "plan", "anticipate", "believe", "estimate",
"predict", "potential", "seem", "seek", "future", "continue", or
"appear" or the negative of these terms or similar expressions,
although not all forward-looking statements contain these
identifying words. Additional information concerning these and
other factors that may cause actual results to differ materially
from those anticipated in the forward-looking statements is
contained in the "Risk Factors" section of the Company's Annual
Report on Form 10-K for the year ended December 31, 2015, and in
the Company's other periodic reports and filings with the
Securities and Exchange Commission. The Company cautions investors
not to place undue reliance on the forward-looking statements
contained in this press release. All forward-looking statements are
based on information currently available to the Company on the date
hereof, and the Company undertakes no obligation to revise or
update these forward-looking statements to reflect events or
circumstances after the date of this press release, except as
required by law.
Contact:
Jack Howarth
Vice President, Corporate Affairs
609-359-3016
jhowarth@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jul 2023 to Jul 2024